mitoxantrone has been researched along with Abnormalities, Drug-Induced in 4 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The experience with mitoxantrone (MIX) especially in the first trimenon is very limited, until now only one case of a pregnant woman with MS who was exposed to MIX in early pregnancy and delivered a growth restricted but healthy child was published." | 3.77 | A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. ( Chan, A; Epplen, J; Gold, R; Hellwig, K; Schimrigk, S, 2011) |
| "This paper describes two cases of acute promyelocytic leukemia diagnosed during the second trimester of pregnancy and the most suitable approach to the management of this situation is analyzed." | 1.29 | Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases. ( Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG, 1995) |
| "Ametantrone acetate is an antineoplastic drug chemically described as 1,4-bis [[2-[(2-hydroxyethyl)-amino] ethyl]amino] -9,10-anthracenedione diacetate salt." | 1.27 | Teratology studies of ametantrone acetate in rats and rabbits. ( Anderson, JA; de la Iglesia, FA; Fitzgerald, JE; Kim, SN; Petrere, JA; Schardein, JL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callegari, I | 1 |
| Derfuss, T | 1 |
| Galli, E | 1 |
| Hellwig, K | 1 |
| Schimrigk, S | 1 |
| Chan, A | 1 |
| Epplen, J | 1 |
| Gold, R | 1 |
| Requena, A | 1 |
| Velasco, JG | 1 |
| Pinilla, J | 1 |
| Gonzalez-Gonzalez, A | 1 |
| Petrere, JA | 1 |
| Kim, SN | 1 |
| Anderson, JA | 1 |
| Fitzgerald, JE | 1 |
| de la Iglesia, FA | 1 |
| Schardein, JL | 1 |
1 review available for mitoxantrone and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; | 2021 |
3 other studies available for mitoxantrone and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Antineoplastic Agents; Female; Humans; Infant, Newb | 2011 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran | 1995 |
Teratology studies of ametantrone acetate in rats and rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Female; Gestati | 1986 |